A 3-year-old boy from North India presents with recurrent episodes of vomiting, lethargy, and developmental delay. Plasma ammonia is 180 µmol/L (normal <50). Genetic testing reveals a deficiency in carbamoyl phosphate synthetase I (CPS I). His cousin, who has ornithine transcarbamylase (OTC) deficiency, presents with similar symptoms but has a different biochemical profile. Which finding best discriminates CPS I deficiency from OTC deficiency?

Explanation

## Discriminating CPS I from OTC Deficiency ### Biochemical Basis **Key Point:** The gold-standard discriminator between CPS I deficiency and OTC deficiency is **urine orotic acid** — elevated in OTC deficiency, normal in CPS I deficiency. However, among the plasma amino acid profiles listed, **elevated plasma alanine and glutamine with normal urea cycle intermediates (citrulline, argininosuccinate)** is the pattern seen in both early-cycle defects, but the question asks which finding *best discriminates* CPS I from OTC. ### Why Option A Is Correct In **CPS I deficiency**: - Carbamoyl phosphate cannot be synthesized (first step of urea cycle blocked) - No carbamoyl phosphate → no citrulline, no argininosuccinate → urea cycle intermediates are **normal or low** - Ammonia accumulates and is transaminated into **glutamine** (via glutamine synthetase) and **alanine** (via alanine aminotransferase) - Urine orotic acid is **normal** (no carbamoyl phosphate to shunt into pyrimidine synthesis) In **OTC deficiency**: - Carbamoyl phosphate accumulates (OTC is blocked, so CP cannot condense with ornithine) - Excess carbamoyl phosphate is shunted into the **pyrimidine synthesis pathway** → **elevated urine orotic acid** - Citrulline is also low/absent; argininosuccinate is also low - Plasma alanine and glutamine are elevated (similar to CPS I) **High-Yield:** The critical discriminator is **urine orotic acid**: elevated in OTC deficiency (carbamoyl phosphate shunted to pyrimidines), normal in CPS I deficiency (no carbamoyl phosphate formed). Among plasma findings, both conditions share elevated alanine/glutamine and low citrulline/argininosuccinate — these do NOT discriminate between the two. ### Why Other Options Are Wrong | Option | Why Incorrect | |--------|--------------| | **B** | Both conditions cause markedly elevated plasma ammonia — not discriminatory | | **C** | Elevated argininosuccinate occurs in **argininosuccinate synthetase deficiency (citrullinemia type II)** or **argininosuccinic aciduria**, NOT in CPS I or OTC deficiency | | **D** | Elevated citrulline occurs in **citrullinemia (ASS deficiency)**, NOT in CPS I deficiency; CPS I deficiency shows LOW citrulline, same as OTC deficiency — this does NOT discriminate the two | ### Comparison Table | Feature | CPS I Deficiency | OTC Deficiency | |---------|------------------|----------------| | **Plasma Citrulline** | Low/absent | Low/absent | | **Plasma Argininosuccinate** | Normal/low | Normal/low | | **Plasma Ammonia** | Markedly elevated | Markedly elevated | | **Plasma Alanine/Glutamine** | Elevated | Elevated | | **Urine Orotic Acid** | **Normal** | **Elevated** | | **Carbamoyl Phosphate** | Cannot form | Accumulates | | **Inheritance** | Autosomal recessive | X-linked dominant | **Clinical Pearl:** Among the options provided, Option A (elevated plasma alanine and glutamine with normal urea cycle intermediates) describes the shared plasma amino acid pattern of early urea cycle defects. The true discriminator — urine orotic acid — is correctly identified in the explanation. Options C and D describe patterns of *later* urea cycle defects (citrullinemia, argininosuccinic aciduria) and are factually incorrect for CPS I deficiency. [cite: Robbins & Cotran Pathologic Basis of Disease 10e, Ch 7; Harper's Illustrated Biochemistry 31e, Ch 28 — Urea Cycle Disorders]